Diabetic Nephropathy - A Drug Pipeline Analysis Report by Technavio

LONDON--(BUSINESS WIRE)-- Technavio has announced their latest drug pipeline analysis report on diabetic nephropathy. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of diabetic nephropathy. The report also includes a study of the pipeline molecules in various stages including, on-going clinical trials, discovery, and pre-clinical.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005112/en/

Diabetic nephropathy: An overview

Diabetic nephropathy is a kidney related complication of type I diabetes and type II diabetes. It is also called diabetic kidney disease. Generally, 4-10 people with diabetes gradually develop kidney diseases. Diabetic nephropathy limits the ability of kidney cells and damages the blood vessels, affecting the organ’s ability to filter out waste. Thus, the waste builds up in the blood instead of being excreted. The best way to prevent or delay diabetic nephropathy is to maintain a healthy lifestyle and treating diabetes and high blood pressure at the right time.

Diabetic nephropathy is one of the major complications that occur in 2-4 out of 10 people with diabetes. In many western countries, diabetic nephropathy is the primary cause of end-stage kidney disease. The prevalence rate of end-stage kidney disease caused by the diabetic nephropathy is increasing every year. For clinical care and epidemiological studies, diabetic nephropathy is characterized by a high urine albumin excretion or a reduced glomerular filtration rate, or both.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Diabetic nephropathy: Segmentation of pipeline molecules

Technavio’s research segments the pipeline molecules based on different phases of drug development including, therapies employed, route of administration (RoA), mechanism of action (MoA), therapeutic modality, and the targets for the drugs under development. In the current drug pipeline, the most preferred RoA remains through the oral mode, with around 60% of the pipeline molecules administered through this mode.

Between companies and institutions, companies led the drug development space for the treatment of diabetic nephropathy. Some of the key players include Bayer, Bird Rock Bio, BLR Bio, CSL, and Dimerix.

Looking for more information? Request your free sample today

Some of the key topics covered in the report include:

1.  Scope of the Report

2.  Regulatory Framework

3.  Drug Development Landscape

• Drugs under development

4.  Drug Development Strategies

• Therapies employed
• Route of administration
• Therapeutic modality
• Mechanism of action

5.  Recruitment Strategies

• Geographical coverage
• Recruitment status
• Gender
• Age

6.  Key Companies

• Type of players
• Company overview

7.  Discontinued and Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180921005112/en/